Zydus Lifesciences extinguishes 87.30 lakh shares post buyback

Corporate Actions View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹1071.00

prior close

₹1070.50

announcement price

After-mkt

timing

Nifty 100market+0.5%+0.9% vs market

Pharmaceuticals peers, median of 162sector+0.4%+1.0% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty 100 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.3

15m

+0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.5+0.9+0.4+1.0

Next day

+3.8-0.7+4.5+1.4+2.4

+2.4-0.0+2.4+1.0+1.4

+2.9+0.1+2.8+0.8+2.1

+5.0-0.4+5.4+0.9+4.1

+3.9-0.7+4.5+2.6+1.2

+2.9+0.6+2.3+2.3+0.6

15d

+5.9+0.0+5.9+4.2+1.6

+5.1-0.1+5.1+2.3+2.8

+3.1+1.1+1.9+2.8+0.2

+8.4-2.5+10.9+7.1+1.4

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences has extinguished 87,30,158 equity shares bought back at INR 1,260 per share under its tender offer buyback worth up to INR 1,100 crore. Post extinguishment, paid-up share capital stands at 99,75,03,832 shares, down from 100,62,33,990. NSDL confirmed the demat credit on June 18, 2026.

Likely market impact

Reduces share count by about 0.87 percent, modestly supporting EPS. Buyback of around 1100 crore signals capital return to shareholders.